1636 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
21 Not yet recruiting Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: BI 836826;   Drug: Ibrutinib
22 Not yet recruiting CyBeR Association in Relapsed/Refractory DLBCL: Phase II Study
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Cytarabine
23 Not yet recruiting Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Conditions: Stage IB Hodgkin Lymphoma;   Stage IIA Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIA Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
24 Not yet recruiting Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
Condition: Leukemia, Lymphocytic, Chronic
Interventions: Drug: ibrutinib;   Drug: obinutuzumab;   Drug: venetoclax
25 Recruiting Gene Therapy for X-linked Chronic Granulomatous Disease
Condition: X-Linked Chronic Granulomatous Disease
Intervention: Genetic: X vivo gene therapy
26 Not yet recruiting Combination of Ibrutinib and As2O3 in the Treatment of CLL
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: Ibrutinib combined with As2O3;   Drug: ibrutinib
27 Not yet recruiting Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax
28 Not yet recruiting A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Are Refractory or Intolerant to B-cell Receptor Inhibitors
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Venetoclax
29 Not yet recruiting A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Conditions: Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B Cell Lymphoma
Interventions: Drug: Buparlisib;   Drug: Ibrutinib
30 Recruiting Chidamide Plus R-CHOP in Elderly DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Chidamide
31 Recruiting Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide
32 Recruiting Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: bendamustine, rituximab
33 Recruiting Reduced Chemotherapy in Low Risk DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone
34 Not yet recruiting Reliability and Validity of Self-measured Arm Circumference in Women With Breast Cancer
Conditions: Lymphedema;   Breast Cancer
Intervention: Procedure: Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference
35 Recruiting An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: AZD 2014;   Drug: Rituximab
36 Not yet recruiting Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin's
Interventions: Drug: Obinutuzumab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin
37 Not yet recruiting Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia
Interventions: Drug: Fludarabine;   Radiation: Fractionated total body irradiation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Drug: Melphalan;   Drug: Granulocyte-colony stimulating factor;   Procedure: Stem cell transplant;   Drug: Azacitidine
38 Not yet recruiting Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery
Conditions: Lymphedema;   Breast Cancer
Interventions: Device: Bio Impedance Analysis Measurement;   Device: Tissue Dielectric Constant Measurement
39 Not yet recruiting Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Conditions: Diffuse Large B Cell Lymphoma;   Primary Mediastinal (Thymic) Large B-cell Lymphoma;   Transformed Indolent Lymphoma;   Recurrent Disease;   Refractory Cancer
Intervention: Drug: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
40 Not yet recruiting Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: ABP 798;   Drug: Rituximab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years